What are the twelve mesenchymal stem cell (MSC) therapies that have regulatory approval and what are their approved indications?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 3, 2026 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Twelve Regulatory-Approved MSC Therapies and Their Indications

As of 2023, there are 12 mesenchymal stem cell (MSC) therapies that have received regulatory approval worldwide, with 9 of these products approved in Asia (particularly South Korea), and the remaining approvals distributed across other regions including Japan, Europe, and most recently the United States. 1

Geographic Distribution of Approved MSC Therapies

  • South Korea leads globally with the highest number of approved MSC therapies, accounting for the majority of the 9 Asian-approved products 1
  • Japan has approved MSC products under their expedited PMD Act regulatory framework, including HeartSheet (autologous skeletal myoblast sheet) for severe heart failure due to ischemic heart disease, approved in 2015 2
  • Europe has approved MSC therapies for graft-versus-host disease and Crohn's fistular diseases 3
  • The United States had no approved MSC therapies until December 2024, when the FDA approved Ryoncil (remestemcel-L-rknd), an allogeneic bone marrow MSC therapy for pediatric acute steroid-refractory graft-versus-host disease, marking the first FDA-approved MSC product 4

Approved Indications

While the specific names and indications of all 12 products are not fully detailed in the provided evidence, the documented approved indications include:

Graft-Versus-Host Disease (GvHD)

  • Pediatric acute steroid-refractory GvHD is treated with Ryoncil (remestemcel-L-rknd) in the United States 4
  • General GvHD has approved MSC therapies in Japan and Europe 3

Cardiovascular Disease

  • Severe heart failure due to ischemic heart disease is treated with HeartSheet (autologous skeletal myoblast sheet) in Japan 2

Inflammatory Bowel Disease

  • Crohn's fistular disease has approved MSC therapies in Europe 3

Liver Disease

  • Liver cirrhosis is treated with autologous mesenchymal stem cell infusion therapy in Japan (classified as Class II medium-risk regenerative medicine) 2

Regulatory Context and Challenges

  • Despite 1,120 registered MSC clinical trials worldwide as of April 2023, only 12 therapies have achieved regulatory approval, reflecting the significant gap between research activity and successful commercialization 1
  • The limited approval rate stems from inconsistent demonstration of efficacy in clinical trials, despite MSCs consistently showing excellent safety profiles 5
  • Japan's expedited approval system under the PMD Act allows conditional/term-limited marketing authorization after Phase 2 trials confirm safety and predict likely efficacy, with subsequent confirmation required within 7 years 2
  • China has zero approved MSC therapies, and all stem cell-based intervention advertisements remain illegal, though widespread unauthorized marketing persists 2

Critical Safety Distinctions Between MSC Sources

Not all MSC products carry equivalent safety profiles, and regulatory approval for one MSC source cannot be extrapolated to others:

  • Bone marrow-derived MSCs (BM-MSCs) trigger weaker Instant Blood-Mediated Inflammatory Reaction (IBMIR) and have the most established safety profile 6
  • Adipose tissue-derived MSCs (AT-MSCs) exhibit the strongest procoagulant activity and have been associated with lethal effects in preclinical models and pulmonary embolism in patients 6
  • Perinatal tissue-derived MSCs (PT-MSCs) from umbilical cord have caused venous thrombosis requiring thrombolytic therapy 6

Common Pitfalls in Clinical Application

  • Avoid assuming all MSC products are equivalent—tissue source fundamentally determines safety profile and thrombotic risk 6
  • Do not administer high-dose MSCs without anticoagulation—the American College of Cardiology and International Society for Stem Cell Research strongly recommend routine low-dose heparin 6
  • Recognize that most "stem cell" products marketed in clinical practice are minimally manipulated cell preparations, not true stem cells, containing only 1 in 1,000 to 1 in 1,000 actual stem or progenitor cells 2
  • Understand that professional organizations including AAOS strongly oppose unproven stem cell therapies (such as for osteoarthritis) due to lack of standardization and product heterogeneity 6

References

2
Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

5
Research

Mesenchymal stromal cell therapy: Progress to date and future outlook.

Molecular therapy : the journal of the American Society of Gene Therapy, 2025

6
Guideline

Mesenchymal Infusion Therapy

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Related Questions

What are the latest updates on mesenchymal stem cell (MSC) therapy, including approved indications and experimental applications?
When should metoprolol succinate (extended‑release) be used instead of metoprolol tartrate (immediate‑release), and what are the dosing differences?
What is the recommended treatment for sudden nocturnal anal cramps caused by internal anal sphincter spasm in a patient with an anal fissure?
What is the appropriate postoperative management after a unilateral knee arthroscopy with meniscectomy and arthroscopic shaving?
What is the recommended peri‑operative management for a unilateral knee arthroscopy with partial meniscectomy and arthroscopic shaving in an otherwise healthy adult?
How should a nephrologist manage a 75‑kg adult with hypertension (blood pressure 140/90 mmHg, pulse 85/min), a history of conservatively treated renal calculi, hypertensive epistaxis, a recent urinary‑tract infection, and fluctuating serum creatinine of 1.2–1.6 mg/dL who is currently taking low‑dose aspirin 75 mg daily and CILACAR‑T (calcium‑channel blocker)?
What is the optimal kidney biopsy sampling protocol, including number of cores, needle gauge, core length, target glomeruli count, and anticoagulant management, to obtain adequate tissue for reliable histologic assessment?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question